相关实验视频

Updated: Jun 8, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

确定miR-451向基因作为扩散大B细胞淋巴瘤的预后标志物

Yi Zhang^1,2, Zichen Wei³, Han Xu¹

¹Department of Gastroenterology, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China.

Expert review of hematology

|November 4, 2024

概括

微RNA-451 (miR-451) 抑制B细胞淋巴瘤的生长,通过抑制增殖,阻止细胞循环,促进细胞亡. 它的向基因显著影响分散型大B细胞淋巴瘤 (DLBCL) 患者的预后.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

B细胞淋巴瘤是一种复杂的癌症,具有多种调节因素.
微RNAs (miRNAs) 是B细胞淋巴瘤开始和进展的关键调节者.
进一步探索miRNA功能,包括miR-451,对于理解B细胞淋巴瘤至关重要.

研究的目的:

研究miR-451在扩散型大B细胞淋巴瘤 (DLBCL) 中的作用.
为了识别miR-451目标基因及其与DLBCL预后的关联.
阐明miR-451影响DLBCL发育的机制.

主要方法:

在人类DLBCL细胞系 (Romas, HBL-1) 中,miR-451的过度表达.
细胞增殖,细胞循环和细胞亡试验.
对GEO数据集的生物信息学分析以识别差异表达基因 (DEG) 和预测miR-451目标.
使用考克斯和拉索回归的DLBCL预后风险模型的开发.
使用qRT-PCR对基因表达的验证.

主要成果:

miR-451的过度表达抑制了DLBCL细胞的增殖.
在DLBCL细胞系中,miR-451诱导细胞周期停止和细胞亡.
生物信息学分析发现了9个与DLBCL预后相关的重要的基因 (MMP9,AQP9,RIN2,EOMES,LCP2,SELPLG,MAL,SOCS5,S1PR3).

结论:

miR-451 在DLBCL发育中起抑制作用.
一组特定的miR-451目标基因显著影响DLBCL患者的结果.
这些发现表明,在DLBCL治疗中涉及miR-451的潜在治疗机制.

关键词:

DLBCL DLBCL 是一个字母.生物信息学是一种生物信息学.扩散大的B细胞淋巴瘤.在 miR-451 系统中,预后预后预后

更多相关视频

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...